genetic supplementation protocols
We develop targeted gene therapies to enhance human longevity, performance and regenerative capacity. Our platform focuses on precision delivery, measurable outcomes, and controlled biological modulation.We are preparing to launch research trials in The Bahamas in 2026.
SYSTEMIC LONGEVITY
Enhance lifespan with a whole-system longevity factor governing cognition, metabolism, and cellular stability.
MUSCLE GROWTH
Unlock strength, improve muscle fiber density, and enhance physical recovery beyond conventional biological limits.
JOINT REGENERATION
Enhance joint performance by releasing the brakes on cartilage repair and suppressing inflammatory states.
MULTI-AXIS STACKS
Personalised gene therapies engineered to maximise performance of gene and cell therapies in all forms.
EARLY ACCESS PROGRAM
Join our upcoming research studies in The Bahamas to enhance resilience, performance, and regenerative capacity, with measured outcomes and concierge service.
Accumsan orci faucibus id eu lorem semper. Eu ac iaculis ac nunc nisi lorem vulputate lorem neque cubilia ac in adipiscing in curae lobortis tortor primis integer massa consequat.
Our Klotho protocol is a systemic gene therapy designed to increase expression of the Klotho hormone, a crucial longevity-associated protein strongly correlated with lifespan, healthy ageing and physiological resilience, and which declines with age in mammals.By adding back extra copies of the Klotho gene, our protocol restores a critical signal that is otherwise lost over time. Rather than impacting a single symptom or biological system, Klotho works enables more youthful signalling across a wide range of metabolic, vascular, neurological, and tissue repair functions. By working across so many systems, Klotho is able to impact lifespan, to slow or reverse ageing in multiple organs.Klotho is an excellent entrypoint for those beginning to engage with frontier systemic longevity medicine. It is already one of the most strongly validated longevity targets: increasing it extends lifespan in mice by ~20–30% and improves physical fitness, reduces muscle fibrosis, improves muscle regenerative capacity, improves bone microstructure, and increases neurogenesis. Conversely, mice completely deficient in Klotho die prematurely, ~15x younger compared to mice with average Klotho levels.Human lifespan improvement data is not yet widely available, as it will take some decades for similar impacts to be shown conclusively given the lifespan of humans vs mice. However, lower blood Klotho has been correlated with higher mortality in adults - and the Human Bioscience Klotho protocol is already verified to improve circulating Klotho levels in humans.Our Klotho gene therapy is delivered using non-viral, non-integrating DNA minicircles carrying additional copies of the Klotho gene into your muscles. This genetic supplementation protocol ensures added expression without permanent modification of your genome. With clinician oversight, our protocol can be administered intravenously for higher expression.Access is limited to screened participants under clinician-led protocols as systemic interventions require baseline assessment, biomarker tracking, and structured follow-up over time.Klotho is not wellness consumption. It is early participation in systemic longevity restoration.
Follistatin is a regenerative gene-delivery protocol to enhance musculoskeletal mass, strength and resilience. It drives systemically measurable lean tissue growth and amplified muscle growth at the site of administration, with consistent performance even in older subjects - all without special diets or training.This genetic supplementation protocol exists to lift the biological constraints on muscle maintenance, recovery, and structural resilience by increasing expression of follistatin, a muscle growth regulatory hormone. Rather than forcing crude growth like anabolic steroids, follistatin inhibits the brakes on muscle growth, allowing the body to resist breakdown and keep what it builds more effectively. For this reason Follistatin is useful for strong young participants, as well as older or frailer participantsFollistatin is extremely well validated, with one of the strongest public translational datasets of any regenerative-growth target. In monkeys, genetic supplementation saw a 15% increase in quadriceps circumference by 8 weeks, and measurable increases in reaction and force, with no abnormal organ pathology or significant safety-signal changes over 15 months.Over 11 weeks, Humanity Bioscience human tests demonstrated statistically significant increases in total lean mass, and higher increases in the injection site (buttocks). In a 35 year old subject, total body mass increased by ~4.6% with lean mass up ~3.8%, and lower-body tissue increased by ~7%, including ~6% lean mass.The follistatin gene therapy protocol is delivered using non-viral, non-integrating DNA minicircles carrying additional copies of the Follistatin gene. Our intent is added expression without permanent genome modification.Follistatin targets skeletal muscle rather than smooth heart or intestinal muscle, and should not be considered a permanent enhancement beyond a few years. Access is limited to screened participants under clinician-led protocols as regenerative signaling interventions require baseline assessment, structured delivery, and functional outcome tracking.This is not enhancement for its own sake. It is early participation in controlled regenerative modulation of the musculoskeletal system.
Chondrepair is a localized gene-silencing protocol for cartilage repair. This program exists to reopen a repair window in damaged joints where cartilage regeneration has stalled, without making a permanent genetic change.In public models that temporary silence our target gene, researchers observerd faster cartilage repair, increased cartilage thickness after injury, and higher growth and repair activity in injured cartilage models. Humanity Bioscience’s own internal mouse experiments (unpublished, forthcoming with the University of Calgary) have documented rapid repair of cartilage injuries in the knee, and a single human volunteer study conducted overseas appears to show reduced pain and inflammation, suggesting at least a slowdown in cartilage degeneration.By directly injecting a silencing RNA into the target joint, we ensure the intervention remains local rather than systemic, and transient rather than permanent, as the RNA degrades. In this way, Chondrepair is a controlled biological intervention, and not a permanent deletion or genomic alteration.As a localized regenerative intervention, Chondrepair requires careful delivery, follow-up, and outcome tracking. Access is therefore limited to screened participants with appropriate joint injuries or degenerative conditions under clinician-led protocols. Several rounds of injection may be considered by Program Participants in conjunction with partner clinics and joint imaging specialists.Chondrepair is not a lifestyle injection like our other protocols, but is instead an early access program for arresting joint degradation and initiating precise joint restoration.
We can combine any set of gene therapies together, or supplement your existing stem cell protocols with your clinician to enhance outcomes.